Respiratory syncytial virus Market: Epidemiology, Therapies, Companies, DelveInsight | Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer

Respiratory syncytial virus therapies, such as ABRYSVO (RSVpreF), BEYFORTUS (nirsevimab), mRNA-1345, VAC 18193 (Ad26.RSV.preF), and others, are expected to boost the Respiratory syncytial virus Market in the upcoming years.

DelveInsight has launched a new report on "Respiratory syncytial virus - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Respiratory syncytial virus, historical and forecasted epidemiology as well as the Respiratory syncytial virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Respiratory syncytial virus market report @ https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Respiratory syncytial virus Market Report:

According to DelveInsight's patient-based model, the respiratory syncytial virus (RSV) market across the seven major markets (7MM) was valued at approximately USD 1.3 billion in 2023. RSV is a widespread virus affecting the respiratory tract, particularly impacting the nose, throat, lungs, and airways.
DelveInsight's epidemiological data shows that the highest incidence of RSV cases in 2023 occurred in children under five, followed by the elderly (65+), with the fewest cases in the 5-64 age group.
Until 2023, RSV treatment primarily focused on supportive care-hydration, nasal suctioning, and nutritional support-especially for bronchiolitis. However, 2023 marked a major shift with the FDA approvals of the first RSV vaccines. AREXVY (RSVPreF3) and ABRYSVO (RSVPreF) were approved for adults aged 60 and older, with ABRYSVO also approved for use during pregnancy-the only RSV vaccine with that indication.
Further expanding preventive options, in 2024, AstraZeneca and Sanofi's monoclonal antibody BEYFORTUS (nirsevimab) was approved in Japan for preventing RSV-related lower respiratory tract infections in infants and young children. Already approved in the US and Europe, it is the only single-dose passive immunization option available for a broad infant population.
Despite these advances, RSV remains a significant public health concern, particularly among infants, young children, and older adults. Awareness remains low among parents and families, and the need for education and prevention strategies is high. Patient advocacy and policy support are essential to increasing vaccine uptake and addressing the unmet need in RSV prevention.
In 2023, there were approximately 8.6 million new cases of respiratory syncytial virus (RSV) across the seven major markets (7MM), with the United States contributing around 56% of these cases. The highest incidence was observed in children under the age of five, who represented nearly half of all RSV cases in the 7MM during that year.
In March 2025, AIM Vaccine Co., Ltd. announced that the FDA had approved a clinical trial for its self-developed mRNA shingles vaccine-its second mRNA vaccine product to receive FDA clearance, following its mRNA RSV vaccine.
In March 2025, Clover Biopharmaceuticals reported that it had received FDA IND approval and enrolled the first participant in a Phase I clinical trial for SCB-1019, a bivalent, non-adjuvanted RSV PreF-Trimer subunit vaccine. The candidate is based on Clover's proprietary Trimer-Tag technology platform.
Key Respiratory syncytial virus companies such as Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others are evaluating new drugs for Respiratory syncytial virus to improve the treatment landscape.
Promising Respiratory syncytial virus therapies include ABRYSVO (RSVpreF), BEYFORTUS (nirsevimab), mRNA-1345, VAC 18193 (Ad26.RSV.preF), and others.

Respiratory syncytial virus Overview

Respiratory Syncytial Virus (RSV) is classified under the *Orthopneumovirus* genus, which is part of the *Pneumoviridae* family and the *Mononegavirales* order. This genus includes human RSV, bovine RSV, and the murine pneumonia virus. Human RSV is divided into two main antigenic subtypes, A and B, which are primarily distinguished by antigenic drift and duplications in the RSV-G gene, along with broader genetic differences throughout the genome, including in the RSV-F gene.

RSV is transmitted through respiratory droplets expelled during coughing, sneezing, or kissing, as well as by touching contaminated surfaces and then touching the eyes, nose, or mouth. The virus can survive for several hours on hard surfaces like tables and crib rails, while its lifespan on soft surfaces such as tissues or skin is shorter. Children are frequently exposed to RSV in environments like schools and daycare centers and can bring the infection home, spreading it to family members. RSV is extremely common, with nearly all children contracting the virus by the age of two.

Respiratory syncytial virus Market Outlook

Despite growing knowledge of the pathogenesis and virology of respiratory syncytial virus (RSV), effective prevention remains limited, and the disease continues to impose a significant health burden. Until 2023, treatment options were primarily restricted to supportive care and the use of prophylactic antibodies. However, the approval of new vaccines like AREXVY and ABRYSVO is expected to significantly transform the treatment landscape.

Historically, RSV management focused on relieving respiratory symptoms-such as wheezing, bronchitis, and dyspnea-using bronchodilators, antibiotics, and general supportive measures. Recently, the emphasis has shifted toward prevention, especially following the introduction of BEYFORTUS (nirsevimab), the first single-dose monoclonal antibody approved for protecting a broad infant population-including those up to 24 months of age-during their first and second RSV seasons.

Nevertheless, there remains a significant unmet need for safe, effective, and affordable RSV prevention and treatment strategies, including antiviral therapies and long-acting monoclonal antibodies. Developing such options presents challenges, particularly around ensuring safety in sensitive populations like infants and pregnant women. Continued innovation in vaccine development is essential to reducing the global burden of RSV.

Discover how the Respiratory syncytial virus market is rising in the coming years @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Respiratory Syncytial Virus Marketed Drugs
ABRYSVO (RSVpreF): Pfizer
BEYFORTUS (nirsevimab): Sanofi/AstraZeneca
Respiratory syncytial virus Emerging Drugs
mRNA-1345: Moderna
VAC 18193 (Ad26.RSV.preF): Janssen
Scope of the Respiratory syncytial virus Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Respiratory syncytial virus Companies: Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others
Key Respiratory syncytial virus Therapies: ABRYSVO (RSVpreF), BEYFORTUS (nirsevimab), mRNA-1345, VAC 18193 (Ad26.RSV.preF), and others
Respiratory syncytial virus Therapeutic Assessment: Respiratory syncytial virus current marketed and Respiratory syncytial virus emerging therapies
Respiratory syncytial virus Market Dynamics: Respiratory syncytial virus market drivers and Respiratory syncytial virus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Respiratory syncytial virus Unmet Needs, KOL's views, Analyst's views, Respiratory syncytial virus Market Access and Reimbursement

To know what's more in our Respiratory syncytial virus report, visit https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Respiratory syncytial virus Market Report:
Respiratory syncytial virus market report covers a descriptive overview and comprehensive insight of the Respiratory syncytial virus Epidemiology and Respiratory syncytial virus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Respiratory syncytial virus market report provides insights into the current and emerging therapies.
The Respiratory syncytial virus market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Respiratory syncytial virus market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Respiratory syncytial virus market.

Got queries? Click here to know more about the Respiratory syncytial virus market Landscape https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Respiratory syncytial virus Patient Share (%) Overview at a Glance
5. Respiratory syncytial virus Market Overview at a Glance
6. Respiratory syncytial virus Disease Background and Overview
7. Respiratory syncytial virus Epidemiology and Patient Population
8. Country-Specific Patient Population of Respiratory syncytial virus
9. Respiratory syncytial virus Current Treatment and Medical Practices
10. Unmet Needs
11. Respiratory syncytial virus Emerging Therapies
12. Respiratory syncytial virus Market Outlook
13. Country-Wise Respiratory syncytial virus Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Respiratory syncytial virus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Respiratory syncytial virus Market Outlook 2034 https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Respiratory syncytial virus Pipeline Insights, DelveInsight

"Respiratory syncytial virus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Respiratory syncytial virus market. A detailed picture of the Respiratory syncytial virus pipeline landscape is provided, which includes the disease overview and Respiratory syncytial virus treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.